Oncotype DX DCIS Can Predict Recurrence in Women With DCIS

A multigene test called Oncotype DX DCIS Score (DCIS Score) was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), a noninvasive breast abnormality, according to data from a large, population-based study presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9—13. The test could provide important individualized information on the risk of recurrence after treatment by breast-conserving surgery, which can help better inform physicians and patients on their future risks and the need for additional treatment.

“We found that the DCIS Score was a good predictor of whether a patient with DCIS who was treated with breast-conserving surgery alone would experience recurrence of DCIS or invasive breast cancer in the same breast,” said Eileen Rakovitch, MD, an associate professor and radiation oncologist at Sunnybrook Health Sciences Centre and scientist at Sunnybrook Research Institute in Toronto, Ontario. “These data confirm the results of a study reported last year but in a more diverse population.

Complete article on AACR's website: http://bit.ly/1worX4m